Loading...
OTCM
KANT
Market cap4mUSD
Jun 27, Last price  
0.34USD
Name

Kineta Inc

Chart & Performance

D1W1MN
OTCM:KANT chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
101.39%
Rev. gr., 5y
13.89%
Revenues
0k
-100.00%
4,312,0008,384,0005,341,0002,840,0005,000,00010,488,0009,091,0001,953,0005,442,0000
Net income
-17m
L+21.51%
-25,040,000-37,232,000-59,432,000-61,832,000-59,125,000-13,877,000-11,960,000-63,067,000-14,099,000-17,132,000
CFO
-12m
L-28.64%
-19,415,000-41,925,000-52,395,000-58,844,000-52,166,0002,296,000-17,853,000-19,029,000-16,209,000-11,567,000
Dividend
Dec 19, 20221.43 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Kineta, Inc., a clinical stage biotechnology company, develops immunotherapies for oncology, neuroscience, and biodefense. It serves private, government, and industry partners. The company has strategic partnerships with Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Kineta, Inc. was formerly known as Lecura, Inc. The company was incorporated in 2007 and is based in Seattle, Washington.
URL
https://kinetabio.com/
IPO date
Feb 11, 2016
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT